BioElectronics Corporation, a U.S.-based company headquartered in Frederick, has been making strides in the field of electromagnetic therapeutic applications. Specializing in the development of innovative products aimed at treating soft tissue trauma, the company has positioned itself as a leader in noninvasive medical technology. Their portfolio includes portable and disposable devices designed to accelerate healing, reduce swelling, and alleviate pain associated with cellular trauma.
As of November 27, 2025, BioElectronics Corp’s close price stood at $0.0003, reflecting a modest performance in the market. The company’s stock is traded on the OTC Bulletin Board, a platform known for hosting smaller, often emerging companies. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $0.0005 on November 4, 2025, and a low of $0.0001 on October 8, 2025.
With a market capitalization of $7,410,000, BioElectronics Corp’s financial metrics indicate a challenging valuation environment, as evidenced by a price-to-earnings ratio of -15. This negative ratio suggests that the company is currently not generating profits, which is not uncommon for companies in the early stages of product development and market penetration.
BioElectronics Corp’s commitment to innovation is evident in its focus on creating therapeutic solutions that are both effective and user-friendly. The company’s products are designed to be noninvasive, catering to a growing demand for treatments that minimize patient discomfort and recovery time. By leveraging electromagnetic technology, BioElectronics aims to provide a viable alternative to traditional therapeutic methods, potentially transforming the landscape of soft tissue injury treatment.
For those interested in learning more about BioElectronics Corporation’s offerings, further information is available on their website, www.bioelectronicscorp.com . The company continues to explore new opportunities and advancements in the field, striving to enhance the quality of life for individuals suffering from soft tissue trauma.
